Market Place
Sourcing Support
All News #Library
Biotech
Gilead Loosens Ties To Arcus As TIGIT Dream Ends In Ph. 3 Fail
21 Apr 2026 //
FIERCE BIOTECH
Arcus Biosciences Unveils 2025 Financials And Pipeline Update
25 Feb 2026 //
BUSINESSWIRE
Arcus` Casdatifan Achieves >1-Year PFS in Kidney Cancer
23 Feb 2026 //
BUSINESSWIRE
Arcus Biosciences To Discuss Q4 2025 Financials & Pipeline
11 Feb 2026 //
BUSINESSWIRE
Arcus Biosciences Announces New Employment Inducement Grants
26 Jan 2026 //
BUSINESSWIRE
Arcus Details 2026 Strategy For Casdatifan And HIF-2a Inhibitor
07 Jan 2026 //
BUSINESSWIRE
Arcus Biosciences to Attend 44th JP Morgan Healthcare Conference
18 Dec 2025 //
BUSINESSWIRE
Arcus Updates Phase 3 STAR-221 Study, Focuses R&D On Casdatifan
12 Dec 2025 //
PHARMIWEB
Arcus Bio Reveals Q3 2025 Financials And Pipeline Update
28 Oct 2025 //
BUSINESSWIRE
Gilead, Arcus Keep TIGIT Dream Alive With 27-Month OS Data
13 Oct 2025 //
FIERCE BIOTECH
Arcus Presents Casdatifan Data, Reveals New Inflammation Programs
06 Oct 2025 //
PHARMAWEB
Arcus Biosciences to Attend Three Investor Conferences
20 Aug 2025 //
BUSINESSWIRE
Arcus Biosciences Announces New Employment Inducement Grants
24 Jul 2025 //
BUSINESSWIRE
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Welireg
03 Jun 2025 //
BIOSPACE
Arcus Biosciences to Present Combination Data at 2025 ASCO Meeting
23 Apr 2025 //
BUSINESSWIRE
Arcus Bioscience to Present Anti-TIGIT Data at SITC Annual Meeting
30 Oct 2024 //
BUSINESSWIRE
Arcus To Test Casdatifan-Volrustomig Combo In Renal Cancer
02 Oct 2024 //
BUSINESSWIRE
Gilead and Arcus Announce Data Showing Clinical Activity of Domvanalimab
07 Nov 2023 //
BUSINESSWIRE
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Show Improvement
03 Jun 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.